Most Recent
Top 10 class action settlements of 2021
Class action settlement totals skyrocketed to over $900 million last year, and one law firm negotiated the lion's share, with $672 million in settlements under its belt.
TWU appeals judgment refusing to reinstate 1,800 outsourced Qantas workers
The Transport Workers Union has appealed a judge's decision that compensation was a more appropriate remedy for 1,800 Qantas workers who had been denied the "matchless blessing" of a job than reinstatement.
Judge shoots down ‘audacious’ McMillan Shakespeare claim for surplus class action funds
A judge has rejected an "audacious" attempt by McMillan Shakespeare to recoup a surplus of funds left over after a $9.5 million class action settlement was distributed to registered group members.
Biogen wins discovery for potential IP lawsuit against Sandoz
Swiss pharmaceutical company Biogen has won discovery of documents sent from Sandoz to the Therapeutic Goods Administration, as it weighs a third patent infringement lawsuit to protect its multiple sclerosis drug against generic reproductions.
TWU loses bid to reinstate 1,800 outsourced Qantas workers
A judge has rejected the TWU's request for the reinstatement of around 1,800 outsourced Qantas workers, finding it was inevitable that the airline would retrench the workers again as soon as lawfully possible.
Under ACCC scrutiny, IVF provider Virtus drops $45M Adora acquisition
IVF company Virtus Health has withdrawn its offer to acquire rival Adora Fertility from Healius, citing the competition regulator's opposition to the takeover.
Funder of Qld energy class action takes on MIS rules in appeal
A litigation funder has taken aim at a landmark judgment in an appeal of a ruling that found its funding arrangement with group members in a class action against Queensland energy suppliers was a managed investment scheme.
‘Full-blooded’ fight brewing between competing a2 Milk class actions
A “full-blooded carriage fight” is set down for next year between two competing class actions alleging dairy giant a2 Milk misled shareholders with an overly optimistic prediction of its infant formula sales.
ACCC staff training ‘inadequate’ during bank cartel probe, court hears
A senior ACCC officer has been grilled on whether staff training on criminal cartel investigations was “inadequate” while the competition regulator ran a cartel probe into ANZ’s $2.5 billion share placement in 2016.
Biogen may sue third generic drug maker to protect MS drug Tecfidera
Swiss pharmaceutical company Biogen is considering a third patent infringement lawsuit against a drug maker to shield its monopoly in Australia for blockbuster multiple sclerosis drug Tecfidera from generic competition.